193 related articles for article (PubMed ID: 9585799)
1. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
4. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
5. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
6. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
Dahl ML; Bertilsson L; Nordin C
Psychopharmacology (Berl); 1996 Feb; 123(4):315-9. PubMed ID: 8867869
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
8. Sequence-based CYP2D6 genotyping in the Korean population.
Lee SY; Sohn KM; Ryu JY; Yoon YR; Shin JG; Kim JW
Ther Drug Monit; 2006 Jun; 28(3):382-7. PubMed ID: 16778723
[TBL] [Abstract][Full Text] [Related]
9. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.
Morita S; Shimoda K; Someya T; Yoshimura Y; Kamijima K; Kato N
J Clin Psychopharmacol; 2000 Apr; 20(2):141-9. PubMed ID: 10770451
[TBL] [Abstract][Full Text] [Related]
10. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
11. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels-A prospective pharmacokinetic study.
Jessurun NT; Vermeulen Windsant A; Mikes O; van Puijenbroek EP; van Marum RJ; Grootens K; Derijks HJ
Br J Clin Pharmacol; 2021 Mar; 87(3):1529-1532. PubMed ID: 32621544
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
18. Quantitative pharmacogenetics of nortriptyline: a novel approach.
Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
Clin Pharmacokinet; 2001; 40(11):869-77. PubMed ID: 11735606
[TBL] [Abstract][Full Text] [Related]
19. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
20. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
